Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct-Dec;10(4):155-162.
doi: 10.4103/picr.PICR_89_18.

Biovigilance: A Global Perspective

Sukhjinder Singh  1 , Shammy Chandel  2 , Phulen Sarma  1 , Dibbanti Harikrishna Reddy  1 , Abhishek Mishra  1 , Subodh Kumar  1 , Prasad Thota  1 , Kotni Murali  1 , Ajay Prakash  1 , Bikash Medhi  1
Affiliations
Review

Biovigilance: A Global Perspective

Sukhjinder Singh et al. Perspect Clin Res. 2019 Oct-Dec.

Abstract

A biological is a substance which either comprises, contains, or is derived from human cells or human tissues. The use of biological products is associated with the risk of infection transmission, allergic reactions, and other adverse events (AEs). The science and activities relating to the detection, assessment, understanding, and prevention of AEs or any other problems related to biological products (blood, cells, tissues, organs, and vaccine in international perspective) are termed as biovigilance. With more and more biologicals being marketed and the rapid revolutionary changes in transplant-related services, the importance of biovigilance is increasing day by day. Although specific types of vigilance systems (pharmacovigilance and materiovigilance) exist, activities related to "biovigilance" are still in an infancy stage. Many developed countries such as the USA, Europe, and Australia have implemented nationwide biovigilance programs. In India, the National Institute of Biologicals, in collaboration with the Indian Pharmacopoeia Commission, has launched the Biovigilance Programme of India. In this article, the biovigilance systems of different countries across the globe have been reviewed along with highlights of the current biovigilance needs.

Keywords: Adverse events; biological products; biovigilance.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Overview of biovigilance
See this image and copyright information in PMC

References

    1. Strong DM, AuBuchon J, Whitaker B, Kuehnert MJ. Biovigilance initiatives. [Last accessed on 2018 May 15];ISBT Sci Ser. 2008 3:77–84. Available from: http://www.doi.wiley.com/10.1111/j. 1751-2824.2008.00168.x .
    1. U.S. Biovigilance Network FAQs. [Last accessed on 2018 May 15]. Available from: http://www.aabb.org/research/hemovigilance/us/Pages/faqs.aspx .
    1. Garzoni C, Ison MG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation. 2011;92:1297–300. - PubMed
    1. Pruett TL, Blumberg EA, Cohen DJ, Crippin JS, Freeman RB, Hanto DW, et al. Aconsolidated biovigilance system for blood, tissue and organs: One size does not fit all. Am J Transplant. 2012;12:1099–101. - PubMed
    1. Busch M, Chamberland M, Epstein J, Kleinman S, Khabbaz R, Nemo G. Oversight and monitoring of blood safety in the United States. Vox Sang. 1999;77:67–76. - PubMed